NCT00923156 - Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Heart Failure

Interventions

DRUG

aliskiren

Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site

DRUG

ramipril

2.5 mg , 5.0 mg or 10 mg once daily

DRUG

Placebo to aliskiren

matching placebo to aliskiren in double blind phase

DRUG

Placebo to ramipril

Matching placebo to ramipril capsule in double blind phase

Trial Locations (16)

12207

Novartis Investigator Site, Berlin

13353

Novartis Investigator Site, Berlin

37057

Novartis Investigator Site, Göttingen

79189

Novartis Investigator Site, Bad Krozingen

80336

Novartis Investigator Site, München

117292

Novartis Investigator Site, Moscow

119620

Novartis Investigator Site, Moscow

121309

Novartis Investigator Site, Moscow

121552

Novartis Investigator Site, Moscow

07747

Novartis Investigator Site, Jena

31-501

Novartis Investigator Site, Krakow

20-090

Novartis Investigator Site, Lublin

61-848

Novartis Investigator Site, Poznan

02-507

Novartis Investigator Site, Warsaw

50-981

Novartis Investigator Site, Wroclaw

Unknown

Novartis Investigative Site, Moscow